Picard Medical (PMI), parent company of SynCardia Systems, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, highlighted a case reported by UCSF Health in which a patient in his twenties with advanced biventricular heart failure was successfully bridged to heart transplantation using the SynCardia Total Artificial Heart. The patient, a male in his twenties, received the SynCardia Total Artificial Heart on November 15, 2025 to restore full circulatory support while awaiting a donor heart. After 119 days of support with the device, the patient underwent a successful heart transplant on March 14, 2026. This case represents the second of five patients at UCSF Health who have been successfully bridged to transplantation using the SynCardia Total Artificial Heart.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMI:
- Investors Sue Picard Medical for Hiding Stock Promotion Scheme
- Picard Medical Highlights Long-Term Total Artificial Heart Success
- Picard announces four-year bridge transplant with Syncardia artificial heart
- Picard Medical Shareholders Approve Expanded Capital Stock Authorization
- Picard Medical Showcases SynCardia Artificial Heart on BTV